Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 20, 2025, titled "Press release relating to audited financial results for the quarter and year ended on March 31, 2025.".
Press Release May 20 2025
Filed with NSE · · 9 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has released its financial performance for the fourth quarter and full year of the fiscal year, detailing significant growth in revenue and profit figures. The Board of Directors has recommended a substantial dividend following the audited results, reflecting strong operational performance. Key highlights include a notable increase in revenue from operations and a marked improvement in EBITDA and net profit compared to the previous year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release May 14 2025
- Press Release May 08 2025
- Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
- Press Release Apr 30 2025
- Press Release Apr 26 2025
Later from Zydus Lifesciences
- Press Release May 23 2025
- Press Release May 28 2025
- Zydus Lifesciences Limited Press Release Jun 02 2025
- Press Release Jun 10 2025
- Press Release Jun 11 2025
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences